Stocks
ImmunityBio, Inc.IBRX
NASDAQHealthcareBiotechnology$8.63+7.29%
Price as of · delayed, not real-time
Focused on developing immunotherapy and cell therapy products for cancer and infectious diseases, ImmunityBio is a clinical-stage biopharmaceutical company. Investors track its progress due to its pipeline targeting high-need oncology indications and partnerships with major research institutions.
Market Cap: $8.6B52W Range: $1.95-$12.43
Congressional Interest in ImmunityBio, Inc. (IBRX)
3 members of Congress have disclosed 4 trades in ImmunityBio, Inc. (IBRX), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
3
Buys
3
Sells
1
Who in Congress Is Trading IBRX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-09-30 | Lisa McClain | buy | $1K-$15K |
| 2026-09-28 | Lisa McClain | buy | $1K-$15K |
| 2023-03-06 | Daniel Goldman | sell | $1K-$15K |
| 2016-11-30 | Jared Polis | buy | $1K-$15K |